In the current market, Xarelto has become a popular alternative to the drug Coumadin for patients seeking to prevent strokes. The drug was developed by Johnson & Johnson and Bayer Health Care, and was marketed as a superior alternative to its competitor because it is allegedly easier to use and requires less frequent monitoring. Unfortunately, it has now come to light that the drug’s use may cause severe side effects in some patients. In some cases, patients have died as a result of severe and uncontrollable bleeding. Many patients and physicians now argue that the drug’s manufacturer did not adequately warn of the risks associated with the drug’s use.
Five Tips About Xarelto Use and the Lack of Adequate Warnings of Risk
Where did Xarelto’s manufacturer go wrong when it came to warning patients and doctors of the risks associated with the drug? The following is an overview:
- Xarelto warnings did not adequately disclose that the drug’s anticoagulant effects may increase the risk of bleeding events.
- The drug’s warnings were not placed prominently in a black box.
- The drug’s warnings failed to disclose the more serious potential outcomes associated with bleeding caused by Xarelto.
- The drug’s warnings obscured information about the lack of a reversal agent.
- The drug’s warnings did not disclose the lack of an available method for doctor’s to quickly reverse the drug’s blood thinning effects and stop bleeding in the event of an emergency.
Many believe that Bayer and Johnson & Johnson placed their desire for profits above consumer safety as a motivation for not providing adequate warnings about the drug’s risks to patients and physicians. The companies may have withheld information about the risks intentionally out of fear that doctors would be less likely to recommend its use over the competitor Coumadin.
Unfortunately, despite its risks, Xarelto has been widely used in the medical community. It is important to spread the word about the dangers of this drug. We encourage you to share a link to this article on your Facebook or Twitter page.